Aligos Therapeutics, Inc. (5WK.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
At close: 08:03AM CEST
| Previous close | 0.5410 |
| Open | 0.5420 |
| Bid | 0.5260 x N/A |
| Ask | 0.5480 x N/A |
| Day's range | 0.5420 - 0.5420 |
| 52-week range | 0.5050 - 1.0200 |
| Volume | |
| Avg. volume | 486 |
| Market cap | 43.114M |
| Beta (5Y monthly) | 2.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now
Aligos Therapeutics (ALGS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- Zacks
After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)
Aligos Therapeutics (ALGS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- Simply Wall St.
Aligos Therapeutics First Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)
Aligos Therapeutics ( NASDAQ:ALGS ) First Quarter 2024 Results Key Financial Results Revenue: US$986.0k (down 64% from...
© 2024 Yahoo. All rights reserved.